Viral FLIP blocks Caspase-8 driven apoptosis in the gut in vivo.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 08 11 2019
accepted: 15 01 2020
entrez: 31 1 2020
pubmed: 31 1 2020
medline: 21 4 2020
Statut: epublish

Résumé

A strict cell death control in the intestinal epithelium is indispensable to maintain barrier integrity and homeostasis. In order to achieve a balance between cell proliferation and cell death, a tight regulation of Caspase-8, which is a key player in controlling apoptosis, is required. Caspase-8 activity is regulated by cellular FLIP proteins. These proteins are expressed in different isoforms (cFLIPlong and cFLIPshort) which determine cell death and survival. Interestingly, several viruses encode FLIP proteins, homologous to cFLIPshort, which are described to regulate Caspase-8 and the host cell death machinery. In the current study a mouse model was generated to show the impact of viral FLIP (vFLIP) from Kaposi's Sarcoma-associated Herpesvirus (KSHV)/ Human Herpesvirus-8 (HHV-8) on cell death regulation in the gut. Our results demonstrate that expression of vFlip in intestinal epithelial cells suppressed cFlip expression, but protected mice from lethality, tissue damage and excessive apoptotic cell death induced by genetic cFlip deletion. Finally, our model shows that vFlip expression decreases cFlip mediated Caspase-8 activation in intestinal epithelial cells. In conclusion, our data suggests that viral FLIP neutralizes and compensates for cellular FLIP, efficiently counteracting host cell death induction and facilitating further propagation in the host organism.

Identifiants

pubmed: 31999759
doi: 10.1371/journal.pone.0228441
pii: PONE-D-19-30669
pmc: PMC6992192
doi:

Substances chimiques

CASP8 and FADD-Like Apoptosis Regulating Protein 0
Cflar protein, mouse 0
Viral Proteins 0
Casp8 protein, mouse EC 3.4.22.-
Caspase 8 EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228441

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Virol. 2009 Mar;83(6):2563-74
pubmed: 19129458
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Nature. 2011 Sep 14;477(7364):335-9
pubmed: 21921917
FEBS J. 2016 Jul;283(14):2701-19
pubmed: 26499289
Int J Mol Sci. 2015 Dec 18;16(12):30321-41
pubmed: 26694384
Nat Immunol. 2002 Mar;3(3):221-7
pubmed: 11875461
Eur J Immunol. 2004 Apr;34(4):941-51
pubmed: 15048704
J Biol Chem. 2002 Apr 19;277(16):13745-51
pubmed: 11830587
Immunol Rev. 2017 May;277(1):76-89
pubmed: 28462525
J Virol. 2008 Feb;82(4):1908-22
pubmed: 18077714
J Biol Chem. 2002 Nov 22;277(47):45162-71
pubmed: 12215447
Gut. 2015 Apr;64(4):601-10
pubmed: 25379949
Biochem Biophys Res Commun. 2016 Nov 4;480(1):23-28
pubmed: 27721066
Gut. 2013 Jul;62(7):1062-71
pubmed: 22689519
J Biol Chem. 2001 Jun 8;276(23):20633-40
pubmed: 11279218
Nature. 1997 Apr 3;386(6624):517-21
pubmed: 9087414
Cell Cycle. 2012 Feb 1;11(3):460-7
pubmed: 22274400
Genesis. 2004 Jul;39(3):186-93
pubmed: 15282745
Gastroenterology. 2013 Dec;145(6):1369-79
pubmed: 24036366
J Clin Invest. 2011 Mar;121(3):1141-53
pubmed: 21339646
Mol Cell Biol. 2001 Jun;21(12):3964-73
pubmed: 11359904
J Virol. 2010 Jan;84(2):1034-46
pubmed: 19906927
J Hum Virol. 2001 Mar-Apr;4(2):62-73
pubmed: 11437316
Oncogene. 1999 Oct 14;18(42):5738-46
pubmed: 10523854
Immunity. 2000 Jun;12(6):633-42
pubmed: 10894163
J Biol Chem. 1999 Jan 15;274(3):1541-8
pubmed: 9880531
J Exp Med. 2004 Apr 5;199(7):993-1003
pubmed: 15067035
Nature. 1997 Jul 10;388(6638):190-5
pubmed: 9217161
Mucosal Immunol. 2018 Nov;11(6):1621-1629
pubmed: 30104627
J Exp Med. 2011 Aug 29;208(9):1889-900
pubmed: 21825016
J Clin Invest. 2011 Jul;121(7):2781-93
pubmed: 21701067
Mol Cell Biol. 2001 Aug;21(16):5299-305
pubmed: 11463813
Exp Cell Res. 2011 Nov 15;317(19):2702-10
pubmed: 21978911
Mol Cell. 2008 Jun 6;30(5):620-31
pubmed: 18538660

Auteurs

Barbara Ruder (B)

Department of Medicine 1, University of Erlangen-Nürnberg, Erlangen, Germany.

Claudia Günther (C)

Department of Medicine 1, University of Erlangen-Nürnberg, Erlangen, Germany.

Michael Stürzl (M)

Division of Molecular and Experimental Surgery, Department of Surgery, University of Erlangen-Nürnberg, Erlangen, Germany.

Markus Friedrich Neurath (MF)

Department of Medicine 1, University of Erlangen-Nürnberg, Erlangen, Germany.

Ethel Cesarman (E)

Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, United States of America.

Gianna Ballon (G)

Department of Pathology and Laboratory Services, Cooper University Health Care, Camden, NY, United States of America.

Christoph Becker (C)

Department of Medicine 1, University of Erlangen-Nürnberg, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH